Does Rallies show Form 4 insider transactions for SPRY?

Yes. Rallies tracks SPRY insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SPRY research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SPRY. It does not provide personalized investment advice.

SPRY (ARS Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

ARS Pharmaceuticals, Inc. Common Stock (SPRY) is a publicly traded Healthcare sector company. As of May 20, 2026, SPRY trades at $7.83 with a market cap of $724.91M and a P/E ratio of -3.83. SPRY moved +8.65% today. Year to date, SPRY is -28.90%; over the trailing twelve months it is -45.57%. Its 52-week range spans $6.66 to $18.90. Analyst consensus is strong buy with an average price target of $27.50. Rallies surfaces SPRY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SPRY stock inside the company?

Recent SPRY insider activity includes Dorsey Brian sold 21.83K, Chakma Justin sold 30.00K, Chakma Justin sold 136.38K, Lowenthal Richard E sold 50.00K, and Scott Kathleen D. sold 12.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SPRY Key Metrics

Key financial metrics for SPRY
Metric	Value
Price	$7.83
Market Cap	$724.91M
P/E Ratio	-3.83
EPS	$-2.00
Dividend Yield	0.00%
52-Week High	$18.90
52-Week Low	$6.66
Volume	1.40M
Avg Volume	0
Revenue (TTM)	$98.99M
Net Income	$-197.98M
Gross Margin	0.00%

Recent SPRY Insider Trades

Dorsey Brian sold 21.83K (~$190.05K) on Nov 13, 2025.
Chakma Justin sold 30.00K (~$267.36K) on Nov 12, 2025.
Chakma Justin sold 136.38K (~$1.21M) on Nov 12, 2025.
Lowenthal Richard E sold 50.00K (~$724.35K) on Aug 21, 2025.
Scott Kathleen D. sold 12.50K (~$187.50K) on Aug 21, 2025.

Latest SPRY News

ARS Pharmaceuticals to Remove CVS Prior Authorizations by July 1 Following 3x Neffy Volume Surge — May 16, 2026
Ars Pharmaceuticals Sees Neffy Prescriptions Triple and Revenue Double in Q1 — May 15, 2026
ARS Pharmaceuticals Q1 Loss of $0.61, Revenue Beats at $22.68M with $17.5M Neffy Sales — May 15, 2026
ARS Pharmaceuticals Appoints Donn Casale to Lead Neffy Expansion and CSU Entry — May 13, 2026
ARS Pharmaceuticals Forecasts 180.8% EPS Drop and 70.3% Revenue Decline — Mar 2, 2026

SPRY Analyst Consensus

3 analysts cover SPRY: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $27.50.

Common questions about SPRY

Who is trading SPRY stock inside the company?: Recent SPRY insider activity includes Dorsey Brian sold 21.83K, Chakma Justin sold 30.00K, Chakma Justin sold 136.38K, Lowenthal Richard E sold 50.00K, and Scott Kathleen D. sold 12.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SPRY?: Yes. Rallies tracks SPRY insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SPRY research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SPRY. It does not provide personalized investment advice.